PDCD1 and melanoma: Preliminary data concerning combination treatment using anti-LAG-3 (BMS-986016, relatlimab) and anti-PD-1 (nivolumab) predict encouraging outcomes with a 16% overall response rate and a 45% disease control rate, especially considering that this study was performed on patients with melanoma who relapsed or were refractory to anti-PD-1/PD-L1 therapy [133].